Trials / Conditions / Adult Acute Eosinophilic Leukemia

Adult Acute Eosinophilic Leukemia

19 registered clinical trials studyying Adult Acute Eosinophilic Leukemia.

Status	Trial	Sponsor	Phase
Unknown	Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Ch NCT02071901	Case Comprehensive Cancer Center	Phase 2
Terminated	Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT01550185	Roswell Park Cancer Institute	Phase 1
Terminated	Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My NCT01260714	National Cancer Institute (NCI)	Phase 1
Terminated	Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory NCT01159301	National Cancer Institute (NCI)	Phase 1
Completed	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00407966	National Cancer Institute (NCI)	Phase 2
Completed	Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Ph NCT00383474	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia NCT00352365	National Cancer Institute (NCI)	Phase 2
Completed	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305	National Cancer Institute (NCI)	Phase 1
Completed	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast NCT00217646	National Cancer Institute (NCI)	Phase 1
Completed	Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemi NCT00131989	National Cancer Institute (NCI)	Phase 1
Terminated	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272	National Cancer Institute (NCI)	Phase 1
Completed	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423	National Cancer Institute (NCI)	Phase 1
Completed	XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797	National Cancer Institute (NCI)	Phase 1
Terminated	Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leuk NCT00101231	National Cancer Institute (NCI)	Phase 1
Terminated	Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid NCT00096148	National Cancer Institute (NCI)	Phase 2
Completed	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Cilengitide in Treating Patients With Acute Myeloid Leukemia NCT00089388	National Cancer Institute (NCI)	Phase 2
Completed	Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia NCT00027872	National Cancer Institute (NCI)	Phase 2
Completed	Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 i NCT00006363	National Cancer Institute (NCI)	Phase 3